Clinical trial
Effectiveness and Safety of TachoSil® Fibrin Sealant Patch in Comparison to a Hydrogel Sealant for Supporting Dural Sealing Among Adult Inpatients in the United States: A Retrospective, Non-Inferiority, Cohort Study
NCT07927413 is registered in ClinicalTrials.gov with Corza Medical GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effectiveness and Safety of TachoSil® Fibrin Sealant Patch in Comparison to a Hydrogel Sealant for Supporting Dural Sealing Among Adult Inpatients in the United States: A Retrospective, Non-Inferiority, Cohort Study
- Lead sponsor
- Corza Medical GmbH
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- February 13, 2026
- Completion date
- November 16, 2026
- Enrollment
- 600 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
cerebrospinal fluid (csf) leak, psuedomeningocele
Arms
As registered; 2 arms.
-
TachoSil®
Adult inpatients who underwent neurological surgery with the use of TachoSil® for dural sealing support and were discharged from US hospitals from 01 January 2017 through 31 March 2026
-
DuraSeal®
Adult inpatients who underwent neurological surgery with the use of DuraSeal® for dural sealing support and were discharged from US hospitals from 01 January 2017 through 31 March 2026
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Risk of Clinically Evident CSF Leak or Clinically Evident Pseudomeningocele
A clinically evident CSF leak is defined as clear fluid leaking through the surgical incision or orifice verified by a glucose concentration test or β-2 transferrin test.
A clinically evident pseudomeningocele is defined as a subcutaneous visible and/or palpable fluid accumulation adjacent to or at the site of surgical incision suspected to be CSF.
If there is not a collection of CSF/pseudomeningocele, or active leak that can be sampled for β-2 transferrin test, but the participant had symptoms consistent with intracranial hypotension and/or an ex vacuo type subdural hematoma, the participant will be considered as having clinically evident CSF leak or pseudomeningocele.
Lead sponsor's other trials
Corza Medical GmbH, most recent start first.